56 -11 (61) 2023 — Ergashov B.B. — FREQUENCY AND RISK OF ARRHITHMIAS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

FREQUENCY AND RISK OF ARRHITHMIAS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

Ergashov B.B.  Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

To date, the relationship between chemotherapy and arrhythmia has not been well studied. We have reviewed the existing literature in order to understand this issue in more detail. Arrhythmias have been reported as a side effect of many chemotherapy drugs.  Anthracyclines are associated with atrial fibrillation (AF) in 2-10% of cases and rarely with ventricular tachycardia (VT)/fibrillation. Taxol and other antimicrotrubic drugs are safe from the point of view of proarrhythmic side effects and do not cause any permanent rhythm disturbances. Arrhythmias caused by 5-fluorouracil, including VT, are mainly of ischemic origin and usually occur in the context of a coronary spasm caused by this drug. Cisplatin, especially with intraperitoneal use, is associated with a very high frequency of AF (12-32%). Melphalan is associated with AF in 7-12% of cases, but apparently it does not cause VT. Interleukin-2 is associated with frequent arrhythmia, mainly with AF. We have studied the available data on arrhythmia caused by chemotherapy. Studies with the intended data collection and thorough analysis are necessary to establish a causal relationship between certain antitumor drugs and arrhythmia.

Keywords: chemotherapy, arrhythmia, atrial fibrillation, ventricular tachycardia

First page

341

Last page

349

For citation: Ergashov B.B. – FREQUENCY AND RISK OF ARRHITHMIAS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY //New Day in Medicine 2023 11(61): 341-349 https://newdaymedicine.com/index.php/2023/11/30/l-544/

LIST OF REFERENCES:

  1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. // CA Cancer J. Clin. 2020;70(1):7-30. DOI: 10.3322/caac.21590
  2. Mariotto A.B., Yabroff K.R., Shao Y. Projections of the cost of cancer care in the United States: 2010-2020. // J. Natl. Cancer Inst. 2011;103(2):117-28. DOI: 10.1093/jnci/djq495. Erratum in: J. Natl. Cancer Inst. 2011; 103 (8): 699.
  3. Koelwyn G.J., Jones L.W., Moslehi J. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. // J. Am. Coll. Cardiol. 2014;64(13):1320-2. DOI: 10.1016/j.jacc.2014.07.949
  4. Markman T.M., Markman M. Cardio-Oncology: mechanisms of cardiovascular toxicity. F1000Res. 2018;7:113. DOI: 10.12688/f1000research.12598.1
  5. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. // Eur. Heart J. 2013;34(15):1102-11. DOI: 10.1093/eurheartj/ehs181
  6. Seliverstova D.V., Evsina O. Cardiotoxicity of chemotherapy. // Russian Heart Journal. 2016;15:50-7 (in Russ.). DOI: 10.18087/rhj.2016.1.2115
  7. Kononchuk N.B., Mitkovskaya N.P., Abramova E.S. et al. Cardiotoxicity induced by cancer chemotherapy breast cancer: risk factors, pathogenesis. // Medical Journal (Minsk). 2013;3(45):4-7 (in Russ.).
  8. Henninger C., Huelsenbeck S., Wenzel P. et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. // Pharmacol. Res. 2015;91:47-56. DOI: 10.1016/j.phrs. 2014.11.003
  9. Tan T.C., Scherrer-Crosbie M. Cardiac complications of chemotherapy: role of imaging. Curr. Treat Options Cardiovasc. Med. 2014;16(4):296. DOI: 10.1007/s11936-014-0296-3
  10. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. // CA Cancer J. Clin. 2012;62(1):10-29. DOI: 10.3322/caac.20138
  11. Faulk A., Weissig V., Elbayoumi T. Mitochondria-specific nanoemulsified therapy for myocardial protection against doxorubicin-induced cardiotoxicity. // Methods Mol. Biol. 2013;991:99-112. DOI: 10.1007/978-1-62703-336-7_11
  12. Eckman D.M., Stacey R.B., Rowe R. Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. // PLoS One. 2013;8(2):e57554. DOI: 10.1371/journal.pone. 0057554
  13. Schwartz R.G., Jain D., Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. // J. Nucl. Cardiol. 2013;20(3):443-64. DOI: 10.1007/s12350-013-9707-1
  14. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat. Rev. Cardiol. 2015; 12 (11): 620. DOI: 10.1038/nrcardio.2015.133. // Erratum for: Nat. Rev. Cardiol. 2015;12(9):547-58.
  15. Herrmann J., Lerman A., Sandhu N.P. et al. Evaluation and management of patients with heart disease and cancer: cardiooncology. // Mayo Clin. Proc. 2014;89(9):1287-306. DOI: 10.1016/j.mayocp.2014.05.013
  16. Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). // J. Am. Coll. Cardiol. 2013;61(23):2355-62. DOI: 10.1016/ j.jacc.2013.02.072
  17. Nohria A. β-Adrenergic blockade for anthracycline- and trastuzumab-induced cardiotoxicity: is prevention better than cure? // Circ. Heart Fail. 2013;6(3):358-61. DOI: 10.1161/ CIRCHEARTFAILURE.113.000267
  18. Sawaya H., Sebag I.A., Plana J.C. et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. // Am. J. Cardiol. 2011;107(9):1375-80. DOI: 10.1016/ j.amjcard.2011.01.006
  19. Motoki H., Koyama J., Nakazawa H. et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. // Eur. Heart J. Cardiovasc. Imaging. 2012;13(1):95-103. DOI: 10.1093/ejechocard/jer172
  20. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. // Int. J. Cardiol. 2016;144:3-15. DOI: 10.1016/j.ijcard.2016.03.003

file

download